Abstract
To establish the clinical breakpoint (CBP) of danofloxacin for Glaesserella parasuis, this study determined three critical cutoff values: the epidemiological cutoff (ECV), the pharmacodynamic cutoff ($CO_{PD}$), and the clinical cutoff ($CO_{CL}$). By analyzing 347 clinical isolates and conducting pharmacokinetic-pharmacodynamic (PK-PD) modeling in both blood plasma and pulmonary epithelial lining fluid (PELF), the research highlights a significant discrepancy between systemic and site-specific drug efficacy. The findings suggest that current resistance levels in wild-type populations may compromise standard treatment, necessitating site-specific breakpoints for accurate clinical guidance.
Introduction
Glaesserella parasuis, a Gram-negative respiratory pathogen, is the causative agent of Glasser’s disease in swine. This condition, characterized by polyserositis, meningitis, and arthritis, poses a severe threat to global porcine health and economic stability. While fluoroquinolones like danofloxacin are frequently employed due to their strong bactericidal activity and excellent tissue distribution, the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have yet to establish formal clinical breakpoints (CBPs) for this specific drug-pathogen pair.
Without established CBPs, veterinarians cannot accurately distinguish between susceptible and resistant strains, leading to potential treatment failures and the further development of antimicrobial resistance. This study aims to fill this gap by establishing CBPs based on microbiological, pharmacodynamic, and clinical data.
Methods and Materials
Microbiological Analysis
The researchers analyzed the Minimum Inhibitory Concentration (MIC) distribution of 347 G. parasuis clinical isolates collected from diseased pigs across China. The epidemiological cutoff (ECV) was calculated using ECOFFinder software to define the upper limit of the wild-type population.
Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
Pharmacokinetic studies were conducted on 12 healthy pigs. Danofloxacin concentrations were measured in both blood plasma and the pulmonary epithelial lining fluid (PELF)—the primary site of infection. A two-compartment model was used for PK analysis, and $CO_{PD}$ was established using Hill formula modeling and Monte Carlo simulations (10,000 iterations) to achieve a 90% probability of target attainment.
Clinical Efficacy Trials
To determine the $CO_{CL}$, clinical trials were performed on 66 infected piglets. The relationship between the probability of cure (POC) and the MIC of the infecting strain was analyzed using the "WindoW" approach, nonlinear regression, and Classification and Regression Tree (CART) analysis.
Key Results
MIC Distribution and ECV
The $MIC_{50}$ and $MIC_{90}$ for danofloxacin against the 347 isolates were 2 $\mu g/mL$ and 8 $\mu g/mL$, respectively. Based on this distribution, the ECV was established at 8 $\mu g/mL$.
Comparative Pharmacokinetics
Danofloxacin demonstrated superior distribution in the lungs compared to the blood. The maximum concentration ($C_{max}$) in PELF was 3.67 $\pm$ 0.25 $\mu g/mL$, significantly higher than the 0.67 $\pm$ 0.01 $\mu g/mL$ observed in plasma. Similarly, the area under the curve (AUC) in PELF (24.28 $\pm$ 2.70 $h\cdot\mu g/mL$) far exceeded that of plasma (4.47 $\pm$ 0.51 $h\cdot\mu g/mL$). The time to reach peak concentration ($T_{max}$) was longer in PELF (1.61 h) than in plasma (0.23 h), indicating sustained accumulation at the site of infection.
Established Cutoff Values
- $CO_{PD}$: 0.125 $\mu g/mL$ (plasma) and 0.5 $\mu g/mL$ (PELF).
- $CO_{CL}$: Calculated between 0.125 and 4 $\mu g/mL$ via the WindoW approach; 0.5 $\mu g/mL$ was ultimately selected as the eligible clinical cutoff.
Discussion: The Site-of-Infection Disparity
The "Lung Advantage"
A pivotal finding of this study is that danofloxacin concentrations in the lungs are 4 to 7 times higher than in the plasma. This suggests that using plasma-based breakpoints alone may lead to "false resistance" classifications, where a drug is labeled ineffective despite reaching therapeutic levels at the actual site of infection (the lungs).
The Resistance Gap
The ECV (8 $\mu g/mL$) is notably higher than both the $CO_{PD}$ and $CO_{CL}$ (0.125–0.5 $\mu g/mL$). This discrepancy indicates that a significant portion of the epidemiological wild-type population has already developed reduced susceptibility. If the clinical breakpoint is set strictly according to clinical success (0.5 $\mu g/mL$), many strains currently circulating in the wild would be classified as resistant, potentially rendering standard danofloxacin dosages ineffective for a large subset of infections.
Conclusion
This study provides the first comprehensive framework for danofloxacin clinical breakpoints against G. parasuis. Based on the integration of microbiological, PK-PD, and clinical data, the recommended clinical breakpoints are 0.25 $\mu g/mL$ for plasma and 8 $\mu g/mL$ for PELF. These findings emphasize the necessity of considering site-specific drug concentrations when treating respiratory infections in swine. Future research should focus on how the inflammatory environment of a diseased lung might further alter these pharmacokinetic parameters and explore the genetic basis of the observed MIC distributions.
Summary updated